Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

Acromegaly and Gigantism Drugs Market Size, Share Global Analysis Report, 2020–2026

report img

Acromegaly and Gigantism Drugs Market By Type (GH Receptor Antagonists, Somatostatin Analogs, Dopamine Agonists, and Others), By Treatment (Medication, Radiation Therapy, and Surgery), and By End-Use (Clinics, Hospitals, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecast 2020–2026

Industry Insights

The acromegaly and gigantism drugs market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire acromegaly and gigantism drugs market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in value (USD Million) from FY 2016 – 2026.

This specialized and expertise-oriented industry research report scrutinizes the technical and commercial business outlook of the acromegaly and gigantism drugs industry. The report analyzes and declares the historical and current trends analysis of the acromegaly and gigantism drugs industry and subsequently recommends the projected trends anticipated to be observed in the acromegaly and gigantism drugs market during the upcoming years.

Acromegaly and Gigantism Drugs Market Size

To know more about this report | Request Free Sample Copy

logoKey Insights from Primary Research

  • According to the primary CXOs of the global acromegaly and gigantism drugs market, the market is estimated to witness a substantial growth of nearly 3.5% over the forecast period.
  • The market was valued at USD 709.5 million, in 2019 and is expected to be valued at over USD 902.6 million.
  • On the basis of the product segment, somatostatin analogs dominated the global acromegaly and gigantism drugs market in 2019. In terms of revenue, it accounted for more than a 35% share of the total market in 2019.
  • Based on various treatments, the global acromegaly and gigantism drugs market was led by medication with more than half of the share of the total market, in 2019.
  • End-use-wise, hospitals were the largest category of the global acromegaly and gigantism drugs market in 2019. It accounted for more than a 48% share of the market in 2019.
  • By geography, the North American region headed the market with a share of above 30%, in 2019.

logoKey Recommendations from Analysts

  • Our analysts recommend that the Asia Pacific region is predicted to witness significant growth over the forecast period.    
  • According to industry expertise, the growth hormone (GH) secreting adenoma in the pituitary gland is the major cause of acromegaly and gigantism.
  • Roll-out compensation plans and programs for rare disease patients are expected to fuel the market’s growth over the years to come.
  • Surging medical and pharmaceutical industries in developing countries such as China, India, South Korea, Brazil, and many other Southeast Asia Countries are likely to cater to the lucrative market’s margin in the future years.
  • According to our analysts, the increasing use of somatostatin analogs with improved administration or dosage schemes; the recent focus on improving patient comfort in this field of chronic disease are expected to drive the growth of the market globally in the near future.

logoMarket Share Analysis by Region

Acromegaly and Gigantism Drugs Market

To know more about this report | Request Free Sample Copy

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the acromegaly and gigantism drugs industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the acromegaly and gigantism drugs industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the acromegaly and gigantism drugs market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the acromegaly and gigantism drugs industry. The acromegaly and gigantism drugs market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the acromegaly and gigantism drugs sector. Key strategic developments in the acromegaly and gigantism drugs market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the acromegaly and gigantism drugs market are appropriately highlighted in the report.

The acromegaly and gigantism drugs market research report delivers an acute valuation and taxonomy of the acromegaly and gigantism drugs industry by practically splitting the market on the basis of different types, categories, and regions.

Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the acromegaly and gigantism drugs industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. Further, country-wise data for the acromegaly and gigantism drugs industries is provided for the leading economies of the world.

Acromegaly and gigantism is a rare conditions and the total incidence of acromegaly ranges from 3.8 to 14.7 cases per 1 lakh person per year, as per Pituitary Journal. The increased prevalence of the disease is one of the key factors expected to drive global market growth in acromegaly and gigantism over the forecast period.

The acromegaly and gigantism drugs market is segmented based on type, treatment, and end-use. On the basis of type segmentation, the market is classified into GH receptor antagonists, somatostatin analogs, dopamine agonists, and others. In terms of treatment segmentation, the market is bifurcated into medication, radiation therapy, and surgery. End-use-wise, the market is segregated into clinics, hospitals, and others.

logoReport Scope

Report Attribute

Details

Market Size in 2019

USD 709.5 Million

Projected Market Size in 2026

USD 902.6 Million

CAGR Growth Rate

3.5% CAGR

Base Year

2019

Forecast Years

2020-2026

Key Market Players

Pfizer Inc., Ionis Pharmaceuticals Inc., Chiasma, Inc., Novartis AG, Crinetics Pharmaceuticals, Ipsen, Midatech Pharma Plc, Novartis AG, and others.

Key Segment

By Drug, Treatment, End-Use, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logoSome of the essential players operating in the acromegaly and gigantism drugs market, but not restricted to include:

  • Pfizer Inc.
  •  Ionis Pharmaceuticals Inc.
  •  Chiasma Inc.
  •  Novartis AG
  •  Crinetics Pharmaceuticals
  •  Ipsen
  •  Midatech Pharma Plc
  •  Novartis AG

The taxonomy of the acromegaly and gigantism drugs industry by its scope and segmentation is as follows:

logo By Drug Type Segmentation Analysis

  • GH Receptor Antagonists
  • Somatostatin Analogs
  • Dopamine Agonists
  • Others

logo By Treatment Segmentation Analysis

  • Medication
  • Radiation Therapy
  • Surgery

logo By End-Use Segmentation Analysis

  • Clinics
  • Hospitals
  • Others

logo Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

  1. CHAPTER 1. Executive Summary
  2. CHAPTER 2. Acromegaly and Gigantism Drugs market – Drug Type Analysis
    1. 2.1. Global Acromegaly and Gigantism Drugs Market – Drug Type Overview
    2. 2.2. Global Acromegaly and Gigantism Drugs Market Share, by Drug Type, 2019 & 2026 (USD Million)
    3. 2.3. GH Receptor Antagonists
      1. 2.3.1. Global GH Receptor Antagonists Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    4. 2.4. Somatostatin Analogs
      1. 2.4.1. Global Somatostatin Analogs Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    5. 2.5. Dopamine Agonists
      1. 2.5.1. Global Dopamine Agonists Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    6. 2.6. Others
      1. 2.6.1. Global Others Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
  3. CHAPTER 3. Acromegaly and Gigantism Drugs market – Treatment Analysis
    1. 3.1. Global Acromegaly and Gigantism Drugs Market – Treatment Overview
    2. 3.2. Global Acromegaly and Gigantism Drugs Market Share, by Treatment, 2019 & 2026 (USD Million)
    3. 3.3. Medication
      1. 3.3.1. Global Medication Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    4. 3.4. Radiation Therapy
      1. 3.4.1. Global Radiation Therapy Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    5. 3.5. Surgery
      1. 3.5.1. Global Surgery Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
  4. CHAPTER 4. Acromegaly and Gigantism Drugs market – End-Use Analysis
    1. 4.1. Global Acromegaly and Gigantism Drugs Market – End-Use Overview
    2. 4.2. Global Acromegaly and Gigantism Drugs Market Share, by End-Use, 2019 & 2026 (USD Million)
    3. 4.3. Clinics
      1. 4.3.1. Global Clinics Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    4. 4.4. Hospitals
      1. 4.4.1. Global Hospitals Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
    5. 4.5. Others
      1. 4.5.1. Global Others Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
  5. CHAPTER 5. Acromegaly and Gigantism Drugs market – Regional Analysis
    1. 5.1. Global Acromegaly and Gigantism Drugs Market Regional Overview
    2. 5.2. Global Acromegaly and Gigantism Drugs Market Share, by Region, 2019 & 2026 (Value)
    3. 5.3. North America
      1. 5.3.1. North America Acromegaly and Gigantism Drugs Market size and forecast, 2016-2026
      2. 5.3.2. North America Acromegaly and Gigantism Drugs Market, by Country, 2019 & 2026 (USD Million)
      3. 5.3.3. North America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026
        1. 5.3.3.1. North America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
      4. 5.3.4. North America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026
        1. 5.3.4.1. North America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
      5. 5.3.5. North America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026
        1. 5.3.5.1. North America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
      6. 5.3.6. U.S.
        1. 5.3.6.1. U.S. Market size and forecast, 2016-2026 (USD Million)
      7. 5.3.7. Canada
        1. 5.3.7.1. Canada Market size and forecast, 2016-2026 (USD Million)
    4. 5.4. Europe
      1. 5.4.1. Europe Acromegaly and Gigantism Drugs Market size and forecast, 2016-2026
      2. 5.4.2. Europe Acromegaly and Gigantism Drugs Market, by Country, 2019 & 2026 (USD Million)
      3. 5.4.3. Europe Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026
        1. 5.4.3.1. Europe Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
      4. 5.4.4. Europe Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026
        1. 5.4.4.1. Europe Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
      5. 5.4.5. Europe Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026
        1. 5.4.5.1. Europe Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
      6. 5.4.6. Germany
        1. 5.4.6.1. Germany Market size and forecast, 2016-2026 (USD Million)
      7. 5.4.7. France
        1. 5.4.7.1. France Market size and forecast, 2016-2026 (USD Million)
      8. 5.4.8. U.K.
        1. 5.4.8.1. U.K. Market size and forecast, 2016-2026 (USD Million)
      9. 5.4.9. Italy
        1. 5.4.9.1. Italy Market size and forecast, 2016-2026 (USD Million)
      10. 5.4.10. Spain
        1. 5.4.10.1. Spain Market size and forecast, 2016-2026 (USD Million)
      11. 5.4.11. Rest of Europe
        1. 5.4.11.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Acromegaly and Gigantism Drugs Market size and forecast, 2016-2026
      2. 5.5.2. Asia Pacific Acromegaly and Gigantism Drugs Market, by Country, 2019 & 2026 (USD Million)
      3. 5.5.3. Asia Pacific Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026
        1. 5.5.3.1. Asia Pacific Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
      4. 5.5.4. Asia Pacific Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026
        1. 5.5.4.1. Asia Pacific Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
      5. 5.5.5. Asia Pacific Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026
        1. 5.5.5.1. Asia Pacific Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
      6. 5.5.6. China
        1. 5.5.6.1. China Market size and forecast, 2016-2026 (USD Million)
      7. 5.5.7. Japan
        1. 5.5.7.1. Japan Market size and forecast, 2016-2026 (USD Million)
      8. 5.5.8. India
        1. 5.5.8.1. India Market size and forecast, 2016-2026 (USD Million)
      9. 5.5.9. South Korea
        1. 5.5.9.1. South Korea Market size and forecast, 2016-2026 (USD Million)
      10. 5.5.10. South-East Asia
        1. 5.5.10.1. South-East Asia Market size and forecast, 2016-2026 (USD Million)
      11. 5.5.11. Rest of Asia Pacific
        1. 5.5.11.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Acromegaly and Gigantism Drugs Market size and forecast, 2016-2026
      2. 5.6.2. Latin America Acromegaly and Gigantism Drugs Market, by Country, 2019 & 2026 (USD Million)
      3. 5.6.3. Latin America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026
        1. 5.6.3.1. Latin America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
      4. 5.6.4. Latin America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026
        1. 5.6.4.1. Latin America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
      5. 5.6.5. Latin America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026
        1. 5.6.5.1. Latin America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
      6. 5.6.6. Brazil
        1. 5.6.6.1. Brazil Market size and forecast, 2016-2026 (USD Million)
      7. 5.6.7. Mexico
        1. 5.6.7.1. Mexico Market size and forecast, 2016-2026 (USD Million)
      8. 5.6.8. Rest of Latin America
        1. 5.6.8.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Acromegaly and Gigantism Drugs Market size and forecast, 2016-2026
      2. 5.7.2. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Country, 2019 & 2026 (USD Million)
      3. 5.7.3. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026
        1. 5.7.3.1. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
      4. 5.7.4. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026
        1. 5.7.4.1. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
      5. 5.7.5. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026
        1. 5.7.5.1. The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
      6. 5.7.6. GCC Countries
        1. 5.7.6.1. GCC Countries Market size and forecast, 2016-2026 (USD Million)
      7. 5.7.7. South Africa
        1. 5.7.7.1. South Africa Market size and forecast, 2016-2026 (USD Million)
      8. 5.7.8. Rest of Middle-East Africa
        1. 5.7.8.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million)
  6. CHAPTER 6. Acromegaly and Gigantism Drugs market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Development
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. CHAPTER 7. Company Profiles
    1. 7.1. Pfizer Inc.
      1. 7.1.1. Company Overview
      2. 7.1.2. Pfizer Inc. Revenue and Gross Margin
      3. 7.1.3. Product portfolio
      4. 7.1.4. Recent initiatives
    2. 7.2. Ionis Pharmaceuticals Inc.
      1. 7.2.1. Company Overview
      2. 7.2.2. Ionis Pharmaceuticals Inc. Revenue and Gross Margin
      3. 7.2.3. Product portfolio
      4. 7.2.4. Recent initiatives
    3. 7.3. Chiasma
      1. 7.3.1. Company Overview
      2. 7.3.2. Chiasma Revenue and Gross Margin
      3. 7.3.3. Product portfolio
      4. 7.3.4. Recent initiatives
    4. 7.4. Inc.
      1. 7.4.1. Company Overview
      2. 7.4.2. Inc. Revenue and Gross Margin
      3. 7.4.3. Product portfolio
      4. 7.4.4. Recent initiatives
    5. 7.5. Novartis AG
      1. 7.5.1. Company Overview
      2. 7.5.2. Novartis AG Revenue and Gross Margin
      3. 7.5.3. Product portfolio
      4. 7.5.4. Recent initiatives
    6. 7.6. Crinetics Pharmaceuticals
      1. 7.6.1. Company Overview
      2. 7.6.2. Crinetics Pharmaceuticals Revenue and Gross Margin
      3. 7.6.3. Product portfolio
      4. 7.6.4. Recent initiatives
    7. 7.7. Ipsen
      1. 7.7.1. Company Overview
      2. 7.7.2. Ipsen Revenue and Gross Margin
      3. 7.7.3. Product portfolio
      4. 7.7.4. Recent initiatives
    8. 7.8. Midatech Pharma Plc
      1. 7.8.1. Company Overview
      2. 7.8.2. Midatech Pharma Plc Revenue and Gross Margin
      3. 7.8.3. Product portfolio
      4. 7.8.4. Recent initiatives
    9. 7.9. Novartis AG
      1. 7.9.1. Company Overview
      2. 7.9.2. Novartis AG Revenue and Gross Margin
      3. 7.9.3. Product portfolio
      4. 7.9.4. Recent initiatives
  8. CHAPTER 8. Acromegaly and Gigantism Drugs — Industry Analysis
    1. 8.1. Acromegaly and Gigantism Drugs Market – Key Trends
      1. 8.1.1. Market Drivers
      2. 8.1.2. Market Restraints
      3. 8.1.3. Market Opportunities
    2. 8.2. Value Chain Analysis
    3. 8.3. Technology Roadmap and Timeline
    4. 8.4. Acromegaly and Gigantism Drugs Market – Attractiveness Analysis
      1. 8.4.1. By Drug Type
      2. 8.4.2. By Treatment
      3. 8.4.3. By End-Use
      4. 8.4.4. By Region
  9. CHAPTER 9. Marketing Strategy Analysis, Distributors
    1. 9.1. Marketing Channel
    2. 9.2. Direct Marketing
    3. 9.3. Indirect Marketing
    4. 9.4. Marketing Channel Development Trend
    5. 9.5. Economic/Political Environmental Change
  10. CHAPTER 10. Report Conclusion
  11. CHAPTER 11. Research Approach & Methodology
    1. 11.1. Report Description
    2. 11.2. Research Scope
    3. 11.3. Research Methodology
      1. 11.3.1. Secondary Research
      2. 11.3.2. Primary Research
      3. 11.3.3. Models
        1. 11.3.3.1. Company Share Analysis Model
        2. 11.3.3.2. Revenue Based Modeling
        3. 11.3.3.3. Research Limitations

        List of Figures

        FIG. 1 Global Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 2 Global Acromegaly and Gigantism Drugs Market Share, by Drug Type, 2019 & 2026 (USD Million)
        FIG. 3 Global GH Receptor Antagonists Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 4 Global Somatostatin Analogs Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 5 Global Dopamine Agonists Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 6 Global Others Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 7 Global Acromegaly and Gigantism Drugs Market Share, by Treatment, 2019 & 2026 (USD Million)
        FIG. 8 Global Medication Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 9 Global Radiation Therapy Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 10 Global Surgery Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 11 Global Acromegaly and Gigantism Drugs Market Share, by End-Use, 2019 & 2026 (USD Million)
        FIG. 12 Global Clinics Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 13 Global Hospitals Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 14 Global Others Acromegaly and Gigantism Drugs Market, 2016-2026 (USD Million)
        FIG. 15 Global Acromegaly and Gigantism Drugs Market Share, by Region, 2019 & 2026
        FIG. 16 North America Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 17 U.S. Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 18 Canada Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 19 Europe Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 20 Germany Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 21 France Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 22 U.K. Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 23 Italy Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 24 Spain Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 25 Rest of Europe Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 26 Asia Pacific Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 27 China Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 28 Japan Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 29 India Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 30 South  Korea Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 31 South-East Asia Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 32 Rest of Asia Pacific Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 33 Latin America Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 34 Brazil Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 35 Mexico Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 36 Rest of Latin America Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 37 The Middle-East and Africa Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 38 GCC Countries Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 39 South Africa Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 40 Rest of Middle-East Africa Acromegaly and Gigantism Drugs Market, 2016-2026
        FIG. 41 Competitor Market Share – Revenue
        FIG. 42 Pfizer Inc. Revenue and Growth Rate
        FIG. 43 Pfizer Inc. Market Share
        FIG. 44 Ionis Pharmaceuticals Inc. Revenue and Growth Rate
        FIG. 45 Ionis Pharmaceuticals Inc. Market Share
        FIG. 46 Chiasma Revenue and Growth Rate
        FIG. 47 Chiasma Market Share
        FIG. 48 Inc. Revenue and Growth Rate
        FIG. 49 Inc. Market Share
        FIG. 50 Novartis AG Revenue and Growth Rate
        FIG. 51 Novartis AG Market Share
        FIG. 52 Crinetics Pharmaceuticals Revenue and Growth Rate
        FIG. 53 Crinetics Pharmaceuticals Market Share
        FIG. 54 Ipsen Revenue and Growth Rate
        FIG. 55 Ipsen Market Share
        FIG. 56 Midatech Pharma Plc Revenue and Growth Rate
        FIG. 57 Midatech Pharma Plc Market Share
        FIG. 58 Novartis AG Revenue and Growth Rate
        FIG. 59 Novartis AG Market Share
        FIG. 60 Market Dynamics
        FIG. 61 Global Acromegaly and Gigantism Drugs – Value Chain Analysis
        FIG. 62 Technology Roadmap and Timeline
        FIG. 63 Market Attractiveness Analysis – By Drug Type
        FIG. 64 Market Attractiveness Analysis – By Treatment
        FIG. 65 Market Attractiveness Analysis – By End-Use
        FIG. 66 Market Attractiveness Analysis – By Region
        FIG. 67 Market Channel
        FIG. 68 Marketing Channel Development Trend
        FIG. 69 Growth in World Gross Product, 2008-2019
        

        List of Tables

        TABLE 1 Global Acromegaly and Gigantism Drugs Market, 2019 & 2026 (USD Million)
        TABLE 2 Global Acromegaly and Gigantism Drugs market, by Drug Type, 2016-2026 (USD Million)
        TABLE 3 Global Acromegaly and Gigantism Drugs market, by Treatment, 2016-2026 (USD Million)
        TABLE 4 Global Acromegaly and Gigantism Drugs market, by End-Use, 2016-2026 (USD Million)
        TABLE 5 Global Acromegaly and Gigantism Drugs market, by Region, 2016-2026 (USD Million)
        TABLE 6 North America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
        TABLE 7 North America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
        TABLE 8 North America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
        TABLE 9 Europe Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
        TABLE 10 Europe Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
        TABLE 11 Europe Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
        TABLE 12 Asia Pacific Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
        TABLE 13 Asia Pacific Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
        TABLE 14 Asia Pacific Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
        TABLE 15 Latin America Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
        TABLE 16 Latin America Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
        TABLE 17 Latin America Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
        TABLE 18 The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Drug Type, 2016-2026 (USD Million)
        TABLE 19 The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by Treatment, 2016-2026 (USD Million)
        TABLE 20 The Middle-East and Africa Acromegaly and Gigantism Drugs Market, by End-Use, 2016-2026 (USD Million)
        TABLE 21 Global Acromegaly and Gigantism Drugs Market - Company Revenue Analysis 2016-2019 (USD Million)
        TABLE 22 Global Acromegaly and Gigantism Drugs Market - Company Revenue Share Analysis 2016-2019(%)
        TABLE 23 Acquisitions and Mergers
        TABLE 24 New Product/Service Launch
        TABLE 25 Research & Development Activities
        TABLE 26 Market Drivers
        TABLE 27 Market Restraints
        TABLE 28 Market Opportunities
        

Industry Major Market Players

  •  Pfizer Inc.
  •  Ionis Pharmaceuticals Inc.
  •  Chiasma Inc.
  •  Novartis AG
  •  Crinetics Pharmaceuticals
  •  Ipsen
  •  Midatech Pharma Plc
  •  Novartis AG